Aurinia to Participate in Upcoming Investor Healthcare Conferences

About this update from Aurinia Pharmaceuticals Inc

ROCKVILLE, Md. & EDMONTON, Alberta --(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will participate in one-on-one meetings with investors at the Leerink Partners Therapeutics Forum : I&I and Metabolism, July 9-10, 2024 , in Boston , and at the 3rd Annual H.C. Wainwright Virtual Kidney Conference , July 15, 2024 . About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021 , the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. The Company’s head office is in Edmonton, Alberta , its U.S. commercial office is in Rockville, Maryland . The Company focuses its development efforts globally. View source version on businesswire.com : https://www.businesswire.com/news/home/20240702079714/en/ Media and Investor Inquiries: Andrea Christopher Corporate Communications and Investor Relations, Aurinia [email protected] [email protected] Source: Aurinia Pharmaceuticals Inc.

View stock analysis, news, and events for Aurinia Pharmaceuticals Inc